Q2 2025 Management View Helmy Eltoukhy, Co-CEO, stated that "Q2 marked another exceptional quarter for Guardant. We continue to build momentum across oncology, biopharma and screening business lines, ...

Diagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company ...

Second Quarter 2025 Results Key Financial Results Revenue: US$232.1m (up 31% from ...

With rates of colorectal cancer (CRC) surging among younger populations, Guardant Health is turning to a famous face beloved ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and ...

James Van Der Beek and Guardant are partnering for a campaign focused on colorectal cancer. Guardant Health announced a ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

Discover Guardant Health's FDA breakthroughs & revenue growth! Learn why profitability-focused investors might hold back ...

Guardant Health has commercially launched Guardant360 ®, Guardant360 ® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients ...

Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and ...

What happened Despite the roaring bull market on Monday, shares of cancer diagnostics specialist Guardant Health(GH -3.52%) fell dramatically. There was little mystery as to why this occurred.

If Guardant Health can capture a significant share of these markets, its long-term returns could make the 360% gain since its IPO look like chump change. I think that this stock has the kind of X ...